Production

Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world. We are the 7th largest generic pharmaceutical company globally with more than 12,000 employees and estimated sales of approximately $3 billion. Our fully integrated operation is comprised of four lines of business: Global Generics; Apobiologix; Global Active Pharmaceutical Ingredients (API); and ApoPharma (Innovative Products). With our worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. We produce 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex will spend $2 billion over the next 10 years on research and development.

Post : Technician

API Manufacturing Bulk Drug Unit.

Post : Shift In-charge - Production

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance.

Indian Drugs and Pharmaceuticals Limited (IDPL) is a Central Public Sector Undertaking wholly owned by the Government of India engaged in manufacture of pharmaceuticals with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur. IDPL was established with main objective of creating self-sufficiency in respect of essential life saving medicines, to free the country from dependence on imports and to provide medicines to the millions at affordable prices and not to make millions from the medicines. IDPL was basically conceived and established as a part of Healthcare Infrastructure and has played a pioneering infra-structural role in the growth of Indian Drug Industry base. Recently, the Company has entered in the field of OTC as well as Surgical Products.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres.

Post : JR.OFFICER/ OFFICER / SR. OFFICER

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. The group has state-of-the-art vertically integrated manufacturing facilities for APIs and Formulations, spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. The group's API production units at Dabhasa and Ankleshwar in Gujarat have received approvals from several regulatory authorities.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Mankind Pharma, the 7^th largest Pharmaceutical Company of India, was incepted in 1995 with a meagre capital of 50 lakhs and 20 employees. Today, we are amongst the top 5 fastest growing Pharmaceutical companies of India with an employee base of more than 10000 and heading towards a turnover of  INR 3000 crores. We aspire to aid the community in leading a healthy life through two parallel objectives: formulating, developing & commercializing medicines and delivering affordable & accessible medication that satisfies urgent medical needs.